Indeed, PARP was cleaved and eIF2α phosphorylated following RITA treatment in MCF7 TP53−/− shD133/D160p53 cells, which is consistent with RITA-associated anti-cancer effects also independent of D133/D160p53. Here, EIF2A is linked to cancer.